Fig. 2. USP12 negatively regulates lung tumour growth.

a Schematic diagram showing the intranasal lentiviral delivery of Cre and USP12 plus Cre (USP12;Cre) in Kras^G12D/+-induced lung tumour (top). LV: lentivirus. Kaplan-Meier plots showing the overall survival of indicated Kras^LSL-G12D/+ mice (n = 5−6) (bottom). Two-sided log-rank test. b Representative images of the lungs and statistical analysis of tumour numbers in indicated mouse lungs of Kras^LSL-G12D/+ mice 8 months after lentiviral infection (mean ± SEM, n = 8 each group). 2-tailed unpaired t-test. c Representative images of H&E-stained lung sections (left) and quantitation of tumour burden in lung lesions described in b (mean ± SEM, n = 20 lung lesions each group) (right). 2-tailed unpaired t-test. d Subcutaneous tumour growth of LLC cells stably transduced with control shRNA (LLC-shCON) or shRNA targeting USP12 (LLC-shUSP12) (mean ± SEM, n = 5 each group). Two-sided Mann-Whitney U-test to calculate the differences between the tumour sizes of two groups at day 22. e Schematic diagram showing generation of single-cell clones from LLC cells. f Tumour growth kinetics of LLC single-cell clones with low (USP12^low) or high (USP12^high) expression of USP12 (n = 3−4 each clone).